Advertisement

Surface plasmon resonance based analysis of the binding of LYAR protein to the rs368698783 (G>A) polymorphic Aγ-globin gene sequences mutated in β-thalassemia

  • Chiara Gemmo
  • Giulia Breveglieri
  • Giovanni Marzaro
  • Ilaria Lampronti
  • Lucia Carmela Cosenza
  • Jessica Gasparello
  • Cristina Zuccato
  • Enrica Fabbri
  • Monica Borgatti
  • Adriana Chilin
  • Alessia FinottiEmail author
  • Roberto GambariEmail author
Research Paper
  • 17 Downloads
Part of the following topical collections:
  1. New Developments in Biosensors

Abstract

Recent studies have identified and characterized a novel putative transcriptional repressor site in a 5′ untranslated region of the Aγ-globin gene that interacts with the Ly-1 antibody reactive clone (LYAR) protein. LYAR binds the 5’-GGTTAT-3’ site of the Aγ-globin gene, and this molecular interaction causes repression of gene transcription. In β-thalassemia patients, a polymorphism has been demonstrated (the rs368698783 G>A polymorphism) within the 5′-GGTTAT-3′ LYAR-binding site of the Aγ-globin gene. The major results gathered from surface plasmon resonance based biospecific interaction analysis (SPR-BIA) studies (using crude nuclear extracts, LYAR-enriched lysates, and recombinant LYAR) support the concept that the rs368698783 G>A polymorphism of the Aγ-globin gene attenuates the efficiency of LYAR binding to the LYAR-binding site. This conclusion was fully confirmed by a molecular docking analysis. This might lead to a very important difference in erythroid cells from β-thalassemia patients in respect to basal and induced levels of production of fetal hemoglobin. The novelty of the reported SPR-BIA method is that it allows the characterization and validation of the altered binding of a key nuclear factor (LYAR) to mutated LYAR-binding sites. These results, in addition to theoretical implications, should be considered of interest in applied pharmacology studies as a basis for the screening of drugs able to inhibit LYAR–DNA interactions. This might lead to the identification of molecules facilitating induced increase of γ-globin gene expression and fetal hemoglobin production in erythroid cells, which is associated with possible reduction of the clinical severity of the β-thalassemia phenotype.

Graphical abstract

Keywords

β-Thalassemia Fetal hemoglobin γ-Globin gene polymorphism Ly-1 antibody reactive clone Surface plasmon resonance 

Abbreviations

HbF

Fetal hemoglobin

HEPES

N-(2-Hydroxyethyl)piperazine-N′-ethanesulfonic acid

LYAR

Ly-1 antibody reactive clone

ODN

Oligodeoxyribonucleotide

poly(dI-dC)

Poly(deoxyinosinic-deoxycytidylic) acid

SPR-BIA

Surface plasmon resonance based biospecific interaction analysis

UTR

Untranslated region

Notes

Acknowledgements

RG is funded by Fondazione Cassa di Risparmio di Padova e Rovigo, Consorzio Interuniversitario per le Biotecnologie, the UE THALAMOSS Project (Thalassemia Modular Stratification System for Personalized Therapy of Βeta-Thalassemia; no. 306201-FP7-HEALTH-2012-INNOVATION-1), the Wellcome Trust (innovator award 208872/Z/17/Z) and AIFA (AIFA-2016-02364887). This research was also supported by Associazione Veneta per la Lotta alla Talassemia, Rovigo.

Compliance with ethical standards

No violation of human rights occurred during this investigation. The collection and processing of the human biological samples for this research were approved by the Ethics Committee of Ferrara District, number 06/2013 (approved on June 20, 2013). The study complies with the Declaration of Helsinki, the principles of good clinical practice, and all further applicable regulations. All samples of peripheral blood were obtained after written documentation of informed consent from patients or their legal representatives. Copies of the written consent were collected for archiving by “Day Hospital for Thalassemia and Hemoglobinopathies, S. Anna Hospital, (Ferrara, Italy). Consent to submit this article was received from all coauthors.

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

216_2019_1987_MOESM1_ESM.pdf (166 kb)
ESM 1 (PDF 165 kb)

References

  1. 1.
    Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12:61–76.CrossRefGoogle Scholar
  2. 2.
    Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245–55.CrossRefGoogle Scholar
  3. 3.
    Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the beta- thalassemias. Cold Spring Harb Perspect Med. 2012;2:a011726.Google Scholar
  4. 4.
    Cappellini MD, Viprakasit V, Taher AT. An overview of current treatment strategies for β-thalassemia. Expert Opin Orphan Drugs. 2014;(7):665–79.Google Scholar
  5. 5.
    Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99:811–20.CrossRefGoogle Scholar
  6. 6.
    Gasparello J, Fabbri E, Bianchi N, Breveglieri G, Zuccato C, Borgatti M, et al. BCL11A mRNA targeting by miR-210: a possible network regulating γ-globin gene expression. Int J Mol Sci. 2017;18(12):2530.CrossRefGoogle Scholar
  7. 7.
    Keikhaei B, Yousefi H, Bahadoram M. Clinical and haematological effects of hydroxyurea in β-thalassemia intermedia patients. J Clin Diagn Res. 2015;9(10):OM01–3.Google Scholar
  8. 8.
    Fibach E, Bianchi N, Borgatti M, Zuccato C, Finotti A, Lampronti I, et al. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol. 2006;77:437–41.CrossRefGoogle Scholar
  9. 9.
    Chen D, Zuo Y, Zhang X, Ye Y, Bao X, Huang H, et al. A genetic variant ameliorates β-thalassemia severity by epigenetic-mediated elevation of human fetal hemoglobin expression. Am J Hum Genet. 2017;101:130–8.CrossRefGoogle Scholar
  10. 10.
    Danjou F, Francavilla M, Anni F, Satta S, Demartis FR, Perseu L, et al. A genetic score for the prediction of beta-thalassemia severity. Haematologica. 2015;100:452–7.CrossRefGoogle Scholar
  11. 11.
    Shen Y, Bassett MA, Gurumurthy A, Nar R, Knudson IJ, Guy CR, et al. Identification of a novel enhancer/chromatin opening element associated with high-level γ-globin gene expression. Mol Cell Biol. 2018;38:e00197–18.CrossRefGoogle Scholar
  12. 12.
    Vinjamur DS, Bauer DE, Orkin SH. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br J Haematol. 2018;180:630–43.CrossRefGoogle Scholar
  13. 13.
    Cui S, Engel JD. Reactivation of Fetal hemoglobin for treating β-thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:177–202.CrossRefGoogle Scholar
  14. 14.
    Martyn GE, Quinlan KGR, Crossley M. The regulation of human globin promoters by CCAAT box elements and the recruitment of NF-Y. Biochim Biophys Acta. 2017;1860:525–36.CrossRefGoogle Scholar
  15. 15.
    Breda L, Motta I, Lourenco S, Gemmo C, Deng W, Rupon JW, et al. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood. 2016;128:1139–43.CrossRefGoogle Scholar
  16. 16.
    Krivega I, Dean A. Chromatin looping as a target for altering erythroid gene expression. Ann N Y Acad Sci. 2016;1368:31–9.CrossRefGoogle Scholar
  17. 17.
    Finotti A, Breda L, Lederer CW, Bianchi N, Zuccato C, Kleanthous M, et al. Recent trends in the gene therapy of β-thalassemia. J Blood Med. 2015;6:69–85.Google Scholar
  18. 18.
    Zhu X, Li B, Pace BS. NRF2 mediates γ-globin gene regulation and fetal hemoglobin induction in human erythroid progenitors. Haematologica. 2017;102(8):e285–8.CrossRefGoogle Scholar
  19. 19.
    Nguyen TK, Joly P, Bardel C, Moulsma M, Bonello-Palot N, Francina A. The XmnI (G)gamma polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 beta-thalassemia intermedia patients. Blood Cell Mol Dis. 2010;45:124–7.CrossRefGoogle Scholar
  20. 20.
    Suzuki M, Yamazaki H, Mukai HY, Motohashi H, Shi L, Tanabe O, et al. Disruption of the Hbs1l-Myb locus causes hereditary persistence of fetal hemoglobin in a mouse model. Mol Cell Biol. 2013;33:1687–95.CrossRefGoogle Scholar
  21. 21.
    Sankaran VG, Menne TF, Šćepanović D, Vergilio JA, Ji P, Kim J, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci U S A. 2011;108:1519–24.CrossRefGoogle Scholar
  22. 22.
    Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science. 2016;351:285–9.CrossRefGoogle Scholar
  23. 23.
    Zhu X, Hu T, Ho MH, Wang Y, Yu M, Patel N, et al. Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with index of hydroxyurea responsiveness. Haematologica. 2017;102:1995–2004.CrossRefGoogle Scholar
  24. 24.
    Orkin SH. Recent advances in globin research using genome-wide association studies and gene editing. Ann N Y Acad Sci. 2016;1368:5–10.CrossRefGoogle Scholar
  25. 25.
    Ghiaccio V, Chappell M, Rivella S, Breda L. Gene Therapy for beta-hemoglobinopathies: milestones, new therapies and challenges. Mol Diagn Ther. 2019;23:173–86.CrossRefGoogle Scholar
  26. 26.
    Antoniani C, Meneghini V, Lattanzi A, Felix T, Romano O, Magrin E, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood. 2018;131:1960–73.CrossRefGoogle Scholar
  27. 27.
    Finotti A, Gambari R. Recent trends for novel options in experimental biological therapy of β-thalassemia. Expert Opin Biol Ther. 2014;14:1443–54.CrossRefGoogle Scholar
  28. 28.
    Dey B, Thukral S, Krishnan S, Chakrobarty M, Gupta S, Manghani C, et al. DNA-protein interactions: methods for detection and analysis. Mol Cell Biochem. 2012;365:279–99.CrossRefGoogle Scholar
  29. 29.
    Ju J, Wang Y, Liu R, Zhang Y, Xu Z, Wang Y, et al. Human fetal globin gene expression is regulated by LYAR. Nucleic Acids Res. 2014;42:9740–52.CrossRefGoogle Scholar
  30. 30.
    Bianchi N, Cosenza LC, Lampronti I, Finotti A, Breveglieri G, Zuccato C, et al. Structural and functional insights on an uncharacterized Aγ-globin-gene polymorphism present in four β0-thalassemia families with high fetal hemoglobin levels. Mol Diagn Ther. 2016;20(2):161–73.CrossRefGoogle Scholar
  31. 31.
    Breveglieri G, Bianchi N, Cosenza LC, Gamberini MR, Chiavilli F, Zuccato C, et al. An Aγ-globin G->A gene polymorphism associated with β039 thalassemia globin gene and high fetal hemoglobin production. BMC Med Genet. 2017;18:93.CrossRefGoogle Scholar
  32. 32.
    Finotti A, Bianchi N, Fabbri E, Borgatti M, Breveglieri G, Gasparello J, et al. Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions. Pharmacol Res. 2015;91:57–68.CrossRefGoogle Scholar
  33. 33.
    Forcada-Nadal A, Forchhammer K. Rubio V. SPR analysis of promoter binding of Synechocystis PCC6803 transcription factors NtcA and CRP suggests cross-talk and sheds light on regulation by effector molecules. FEBS Lett. 2018;592:2378.CrossRefGoogle Scholar
  34. 34.
    Zheng D, Worthington J, Timms JF, Woo P. HNRNPA1 interacts with a 5'-flanking distal element of interleukin-6 and upregulates its basal transcription. Genes Immun. 2013;14:479–86.CrossRefGoogle Scholar
  35. 35.
    van Dijk M, Bonvin AM. 3D-DART: a DNA structure modeling server. Nucleic Acids Res. 2009;37:W235–9.CrossRefGoogle Scholar
  36. 36.
    Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4:435–47.CrossRefGoogle Scholar
  37. 37.
    de Vries SJ, van Dijk M, Bonvin AM. The HADDOCK webserver for data-driven biomolecular docking. Nat Protocol. 2010;5:883–97.CrossRefGoogle Scholar
  38. 38.
    DeLano WL. The PyMOL molecular graphics system. San Carlos: DeLano Scientific; 2002.Google Scholar
  39. 39.
    Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB2PQR:an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004;32:W665–7.CrossRefGoogle Scholar
  40. 40.
    Li ZL, Nagahori K, Kawata S, Omotehara T, Ogawa Y, Miyaso H, et al. Using artificial dna sequence to suppress non-specific bindings in crude nuclear extract during surface plasmon resonance assay. Tokai J Exp Clin Med. 2018;43:122–31.Google Scholar
  41. 41.
    Su X, Neo SJ, Peh WY, Thomsen JS. A two-step antibody strategy for surface plasmon resonance spectroscopy detection of protein-DNA interactions in nuclear extracts. Anal Biochem. 2008;376:137–43.CrossRefGoogle Scholar
  42. 42.
    Neo SJ, Su X, Thomsen JS. Surface plasmon resonance study of cooperative interactions of estrogen receptor alpha and transcriptional factor Sp1 with composite DNA elements. Anal Chem. 2009;81:3344–9.CrossRefGoogle Scholar
  43. 43.
    Deng N, Wickstrom L, Cieplak P, Lin C, Yang D. Resolving the ligand-binding specificity in c-MYC G-quadruplex DNA: absolute binding free energy calculations and SPR experiment. J Phys Chem B. 2017;121:10484–97.CrossRefGoogle Scholar
  44. 44.
    Anggayasti WL, Mancera RL, Bottomley S, Helmerhorst E. The effect of physicochemical factors on the self-association of HMGB1: a surface plasmon resonance study. Biochim Biophys Acta. 2016;1864:1620–9.CrossRefGoogle Scholar
  45. 45.
    Wang S, Poon GM, Wilson WD. Quantitative investigation of protein-nucleic acid interactions by biosensor surface plasmon resonance. Methods Mol Biol. 2015;1334:313–32.CrossRefGoogle Scholar
  46. 46.
    Morya VK, Son M, Lee HB, Eun-ki EK. Design and optimization of SPR-based binding assay for evaluation and screening of MITF-E-box binding inhibitor. Mol Biotechnol. 2014;56:265–73.CrossRefGoogle Scholar
  47. 47.
    Zhang D, Han J, Lu W, Lian F, Wang J, Lu T, et al. Discovery of alkoxy benzamide derivatives as novel BPTF bromodomain inhibitors via structure-based virtual screening. Bioorg Chem. 2019;86:494–500.CrossRefGoogle Scholar
  48. 48.
    Jacob NT, Miranda PO, Shirey RJ, Gautam R, Zhou B, de Orbe Izquierdo ME, et al. Synthetic molecules for disruption of the MYC protein-protein interface. Bioorg Med Chem. 2018;26:4234–9.CrossRefGoogle Scholar
  49. 49.
    Chen L, Lv D, Chen X, Liu M, Wang D, Liu Y, et al. Biosensor-based active ingredients recognition system for screening STAT3 ligands from medical herbs. Anal Chem. 2018;90:8936–45.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Chiara Gemmo
    • 1
  • Giulia Breveglieri
    • 1
  • Giovanni Marzaro
    • 2
  • Ilaria Lampronti
    • 1
  • Lucia Carmela Cosenza
    • 1
  • Jessica Gasparello
    • 1
  • Cristina Zuccato
    • 1
  • Enrica Fabbri
    • 1
  • Monica Borgatti
    • 1
  • Adriana Chilin
    • 2
  • Alessia Finotti
    • 1
    Email author
  • Roberto Gambari
    • 1
    • 3
    Email author
  1. 1.Department of Life Sciences and BiotechnologyUniversity of FerraraFerraraItaly
  2. 2.Department of Pharmaceutical and Pharmacological SciencesUniversity of PaduaPaduaItaly
  3. 3.Interuniversity Consortium for BiotechnologyUniversity of TriesteTriesteItaly

Personalised recommendations